The Food and Drug Administration (FDA) will allow trials of a Cuban lung cancer vaccine to proceed in the U.S., according to New York Gov. Andrew Cuomo (D).

ADVERTISEMENT

The trials will be conducted by the New York-based Roswell Park Cancer Institute, Cuomo announced Wednesday, which is teaming up with Cuba’s Center of Molecular Immunology to introduce the vaccine in the U.S.

“We are this much closer to making a breakthrough that will combat cancer and save lives,” said Cuomo, who claimed credit for paving the way for the partnership during his 2015 diplomatic trip to Havana.

Roswell Park will begin clinical trials of the drug, known as CIMAvax-EGF, with about 60 to 90 patients in November, according to the governor.

The lung cancer drug was introduced in Cuba several years ago and has been used to treat more than 4,000 patients around the world. It costs about $1 per shot, according to reports.

The FDA declined to comment on Cuomo's announcement.